Pneumococcal Vaccine: What You Need to Know



booster approval pfizer :: Article Creator

New COVID Booster: Eligibility And Benefits Explained

New COVID Booster: Eligibility And Benefits Explained

New COVID Booster: Eligibility And Benefits Explained

Recently, Australia's prescription medicine regulator Therapeutic Goods Administration (TGA) approved a new COVID booster created by Pfizer. This new booster targets the JN.1 sub-variant of Omicron,  marking the fifth iteration of COVID-19 vaccines. With the virus rapidly evolving, vaccines have been regularly updated to provide continued protection. Nearly five years into the pandemic, this new booster raises several questions such as Why do we need yet another type of booster, and should we continue getting vaccinated? Here's a breakdown of what to consider regarding the new COVID booster and who should get it.

Targeting the Spike Protein

This new booster, as well as other vaccines in the market, are based on mRNA technology. This technology works by instructing our cells to produce a protein found on the surface of the SARS-CoV-2 virus, specifically this protein is known as the spike protein. The spike protein is essential is vital for the virus to attract to enter human cells, and by the production of antibodies to this protein, the virus can be neutralized.

However, as the virus continues to mutate, the spike protein changes as well. This is due to what's known as immune pressure: as our immune systems get better at recognizing the virus, the virus adapts by modifying its structure to evade recognition. Since the onset of the pandemic, Omicron sub-variants like JN.1 have emerged, making vaccines targeting older strains less effective. The JN.1 sub-variant, first detected in August 2023, has since spawned additional sub-variants, further complicating efforts to keep up with the virus's evolution.

The spike protein consists of 1,273 amino acids, which can mutate over time, changing the structure of the protein. This allows the virus to escape some of the antibodies generated by previous infections or vaccinations. It makes it crucial for vaccine developers to constantly update their formulas in order to ensure the spike proteins in vaccines closely match those present in the virus circulating in the population. The better the match between the vaccine and the virus's spike protein, the better the protection it offers.

Who Should Get Vaccinated, and When?

Updating vaccines for mutating viruses is not a new concept. For example, the flu vaccine has been updated every year since the 1950s to keep up with the influenza virus. However, unlike the flu, COVID-19 has not yet settled into a predictable annual cycle. COVID-19 continues to appear in waves, making it a constant challenge. Additionally, COVID-19 is much more contagious than the flu, with estimates showing that one person infected with the JN.1 sub-variant can spread it to five others, compared to just 1.3 for the flu. This makes COVID more difficult to contain.

Furthermore, immunity from COVID vaccinations (or previous infections) tends to wane over time, meaning boosters are needed to maintain high levels of protection. For certain vulnerable populations, this may require more frequent boosters than the annual doses recommended for the general population.

The TGA recommends that people aged 65 to 74 receive a COVID booster every 12 months, though they are eligible every six months. For those aged 75 and older, the recommendation is to get a booster every six months. Adults between the ages of 18 and 64 are eligible for a booster every 12 months unless they have a severe immune deficiency. Conditions such as autoimmune diseases, diabetes, lung disease, and certain cancer treatments are examples of conditions that could make someone eligible for more frequent boosters.

Making Sense of the Advice

It is expected that the Pfizer booster will be providing protection against the JN.1 sub-variant of Omnicorn, which has been predicted to dominate in the upcoming months. Although the TGA's approval of the JN.1 booster is a step forward, the Australian Technical Advisory Group on Immunisation will need to provide further guidance before it becomes widely available. The rollout is expected to take place within the next month, potentially ahead of the holiday season for it is a time when many people gather with family and friends.

In the meantime, the XBB.1.5 vaccines remain available. While these vaccines were designed for an earlier Omicron sub-variant, they still offer some level of protection against the virus. It is expected that younger, healthier individuals may prefer to wait for the new JN.1-targeted booster, while vulnerable groups may benefit from getting vaccinated with whatever booster is currently available.

In vulnerable groups such as older adults and those with weakened immune systems, it is highly advised to get vaccinated regularly as these people are at a higher risk of severe illness, hospitalization, and death from COVID-19. For those with stronger immune systems and in healthy conditions, the vaccine can lower the risk of developing long COVID, a lingering condition that can affect multiple organ systems.

Do You Need a COVID Booster?

While the vaccines provide excellent protection against severe disease, it's important to remember that they do not guarantee immunity from infection. COVID-19 vaccines are less effective at preventing mild illness or breakthrough infections, but they remain our best defense against severe disease and hospitalization. The evidence on whether vaccines reduce transmission of the virus is mixed, but there is consensus that vaccination reduces the overall burden of disease.

The rollout of the new Pfizer booster marks an important step in managing the ongoing COVID-19 threat. With the virus continuing to mutate and evolve, it is likely that future updates to the vaccine will be necessary to keep pace with new variants. However, it's clear that vaccination remains a vital tool in reducing the impact of COVID-19 on both public health and individual lives.

As the holiday season and social gatherings approach, getting vaccinated can provide an extra layer of protection against the virus and help prevent community outbreaks. If you're due for a booster or have concerns about your vaccination, it's a good idea to talk to your healthcare provider to determine the best option based on your health and risk factors.

While it may take a considerable amount of time for COVID-19 to fade away, updated vaccines can help curb the severity of the illness, protect vulnerable groups, and assist in managing future waves of infection. Vaccinations stand as a vital tool in the ongoing fight against COVID-19 as we continue to live with the virus.


We Now Know When A New COVID Vaccine Will Be Released. Should You Get A Booster?

Australia will soon roll out a new COVID-19 vaccine, with the updated designed to target a different subvariant of the disease to previous vaccines. The Department of Health and Aged Care has confirmed Pfizer's JN.1 vaccine is set to be available from 9 December.

The department also confirmed the immunisation guidelines will be refreshed in the coming weeks to include updated advice for the new vaccine.

READ MORE

A new COVID-19 vaccine has been approved for Australians. Here's what to know

The Therapeutic Goods Administration (TGA) confirmed to SBS News in October the shot had been approved for people over six months old. Professor Nathan Bartlett, an immunology researcher from the University of Newcastle, told SBS News the new vaccine is based on exactly the same formulation as the previous Pfizer vaccine, just encoded for the new subvariant. "It's just a matter of tweaking the sequence of the RNA essentially but biochemically the vaccine is is identical and so it has exactly the same safety profile as previous mRNA vaccines," he said.

The TGA and ATAGI also closely monitor all current and emerging evidence on COVID-19 vaccines, including safety and efficacy data.

READ MORE

Why Australia could miss out on Moderna's new COVID-19 vaccine

What will the new vaccine target? The new vaccine targets the Omicron subvariant JN.1, which gave way to two subsets of variants dubbed 'FLiRT' and 'FLuQE'. While FLuQE is currently dominant in Australia, the new Pfizer shot should protect against it. The most recent vaccine update Australia had was in late 2023 and Professor Paul Griffin, an infectious diseases researcher from the University of Queensland, said the protection Australians are getting from current vaccines targeting the omicron subvariant XBB.1.5 has declined. "The virus has changed a lot this year and we've still been using vaccines targeting XBB, which hasn't been the most prevalent subvariant for quite some time," he said.

"These updates to target JN.1are going to be really important and I mean, these vaccines will give better protection than the boosters we've been using thus far".

READ MORE

'Confusion and concern': TGA takes aim at COVID vaccine contamination misinformation

What about boosters? Both Griffin and Bartlett said the current guidelines on booster shots can be confusing because people may feel unsure of what being 'eligible' means for booster shots, as compared to shots being 'recommended'. Bartlett said that for people over 18 years old who are immunocompromised or people aged 75 years or over, booster shots are recommended every six months, as they are more likely to develop severe disease.

But for younger adults and those who aren't immunocompromised, the language is less strong and it's more "a case of personal choice", Bartlett said.

READ MORE

Australia's COVID vaccine compensation scheme is closing. Here's how much it has paid out

Griffin described booster shots as "a bit of a minefield at the moment" and said the government recommendations need to be clarified, as the uptake of booster shots is low. Data from the Australian Immunisation Register last year found 16.6 million adults nationally hadn't had a COVID-19 vaccine in the last six months, while 2.9 million had. Griffin said there are a lot of reasons to consider getting vaccinated and individual risks like travelling and what people do for work should factor into those considerations.

"It's not clear-cut but basically for most people, once a year should be what you strongly consider getting a booster for, particularly if you've got any additional risk factors," Griffin said.

READ MORE

Should you get another COVID jab? The booster advice has been updated

Why is Australia so behind? While the JN.1 vaccine is hitting Australia soon, it has been available in other parts of the world for months. In June, the US Food and Drug Administration advised all vaccines should target JN.1 and in the time Australia has taken to approve roll out these vaccines, the United States has even updated vaccines to target a newer subvariant, KP.2. "We're quite a way behind, which, while we certainly want to encourage our rigorous processes to make sure that we have all the necessary data and necessary approvals in our country, it has been a little bit frustrating," Griffin said. Griffin said Australia is traditionally behind other countries in vaccine approval and "we do need to be able to do this more efficiently so that people can benefit from our updated vaccines as quickly as possible."

"We are potentially experiencing another wave now or soon and we're only just getting these vaccines available and the virus has continued to change — so we do get reduced impact from these updates if there's a delay to having them available," he said.


Australia Approves New COVID Booster Targeting Omicron Sub-Variant

Australia's Therapeutic Goods Administration (TGA) has given the green light to Pfizer's latest COVID booster targeting the JN.1 sub-variant of Omicron. This marks the fifth evolution of COVID vaccines designed to keep up with the fast-changing SARS-CoV-2 virus.

The new booster utilizes mRNA technology to instruct cells to produce the spike protein, crucial for the virus's attachment to cells. This advancement aims to improve immune response amid ongoing viral mutations, including the new Omicron sub-variants JN.1, KP.2, KP.3, and XEC.

Despite uncertainties surrounding COVID's seasonal cycles, boosters remain vital, particularly for vulnerable populations. Older adults and those with severe immune deficiencies are advised to stay up-to-date with vaccinations, as immunity can diminish over time.

(With inputs from agencies.)






Comments